<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Deep Dive: AI Classifier to Predict Docetaxel Benefit in Prostate Cancer - Sebastian Medina</title>

    <!-- SEO Meta Tags -->
    <meta name="description" content="A detailed analysis of our Clinical Cancer Research paper on using artificial intelligence to predict which prostate cancer patients will benefit from docetaxel chemotherapy.">
    <meta name="author" content="Sebastian Medina">
    <meta name="keywords" content="computational pathology, prostate cancer, precision oncology, APIC, docetaxel, AI, machine learning, biomarker">

    <!-- Highwire Press / Google Scholar Meta Tags -->
    <meta name="citation_title" content="A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer">
    <meta name="citation_author" content="Medina, Sebastian">
    <meta name="citation_author" content="Tokuyama, Naoto">
    <meta name="citation_author" content="Hammouda, Kamal">
    <meta name="citation_author" content="Pathak, Tilak">
    <meta name="citation_author" content="Mirtti, Tuomas">
    <meta name="citation_author" content="Madabhushi, Anant">
    <meta name="citation_publication_date" content="2025">
    <meta name="citation_journal_title" content="Clinical Cancer Research">
    <meta name="citation_issn" content="1078-0432">
    <meta name="citation_doi" content="10.1158/1078-0432.CCR-25-3327">
    <meta name="citation_pdf_url" content="https://doi.org/10.1158/1078-0432.CCR-25-3327">

    <!-- Dublin Core Meta Tags for Altmetric -->
    <meta name="DC.identifier" content="doi:10.1158/1078-0432.CCR-25-3327">
    <meta name="DC.title" content="A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer">
    <meta name="DC.creator" content="Medina, Sebastian">
    <meta name="DC.date" content="2025">
    <meta name="DC.publisher" content="Clinical Cancer Research">
    <meta name="DC.type" content="article">

    <!-- Open Graph Meta Tags for Social Sharing -->
    <meta property="og:title" content="Deep Dive: AI Classifier to Predict Docetaxel Benefit in Prostate Cancer">
    <meta property="og:description" content="Analysis of our Clinical Cancer Research paper on AI-based predictive biomarkers for prostate cancer treatment selection.">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://srmedinac.github.io/blog/apic-docetaxel-prediction.html">
    <meta property="og:site_name" content="Sebastian Medina">
    <meta property="article:published_time" content="2025-01-05">
    <meta property="article:author" content="Sebastian Medina">
    <meta property="article:tag" content="computational pathology">
    <meta property="article:tag" content="prostate cancer">
    <meta property="article:tag" content="precision oncology">

    <!-- Twitter Card Meta Tags -->
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="Deep Dive: AI Classifier to Predict Docetaxel Benefit in Prostate Cancer">
    <meta name="twitter:description" content="Analysis of our Clinical Cancer Research paper on AI-based predictive biomarkers for prostate cancer treatment selection.">

    <!-- Canonical URL -->
    <link rel="canonical" href="https://srmedinac.github.io/blog/apic-docetaxel-prediction.html">

    <!-- Favicon -->
    <link rel="icon" type="image/svg+xml" href="/favicon.svg">
    <link rel="icon" type="image/x-icon" href="/favicon.ico">
    <link rel="icon" type="image/png" sizes="32x32" href="/favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="/favicon-16x16.png">
    <link rel="apple-touch-icon" sizes="180x180" href="/apple-touch-icon.png">

    <link rel="stylesheet" href="../styles.css">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">

    <!-- Structured Data for Search Engines and Altmetric -->
    <script type="application/ld+json">
    {
      "@context": "https://schema.org",
      "@type": "BlogPosting",
      "headline": "Deep Dive: An AI-Based Pathology Classifier to Predict Docetaxel Benefit in Prostate Cancer",
      "author": {
        "@type": "Person",
        "name": "Sebastian Medina",
        "url": "https://srmedinac.github.io",
        "affiliation": {
          "@type": "Organization",
          "name": "Georgia Institute of Technology and Emory University"
        }
      },
      "datePublished": "2025-01-05",
      "description": "A detailed analysis of our Clinical Cancer Research paper on using artificial intelligence to predict which prostate cancer patients will benefit from docetaxel chemotherapy.",
      "keywords": ["computational pathology", "prostate cancer", "precision oncology", "APIC", "docetaxel", "AI biomarker"],
      "mainEntityOfPage": {
        "@type": "WebPage",
        "@id": "https://srmedinac.github.io/blog/apic-docetaxel-prediction.html"
      },
      "about": {
        "@type": "ScholarlyArticle",
        "@id": "https://doi.org/10.1158/1078-0432.CCR-25-3327",
        "name": "A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer",
        "headline": "A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer",
        "author": [
          {"@type": "Person", "name": "Sebastian Medina"},
          {"@type": "Person", "name": "Naoto Tokuyama"},
          {"@type": "Person", "name": "Kamal Hammouda"},
          {"@type": "Person", "name": "Tilak Pathak"},
          {"@type": "Person", "name": "Tuomas Mirtti"},
          {"@type": "Person", "name": "Anant Madabhushi"}
        ],
        "datePublished": "2025",
        "isPartOf": {
          "@type": "PublicationIssue",
          "isPartOf": {
            "@type": "Periodical",
            "name": "Clinical Cancer Research",
            "issn": "1078-0432",
            "publisher": {
              "@type": "Organization",
              "name": "American Association for Cancer Research"
            }
          }
        },
        "url": "https://doi.org/10.1158/1078-0432.CCR-25-3327",
        "sameAs": [
          "https://doi.org/10.1158/1078-0432.CCR-25-3327",
          "https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-25-3327"
        ],
        "identifier": {
          "@type": "PropertyValue",
          "propertyID": "doi",
          "value": "10.1158/1078-0432.CCR-25-3327"
        }
      }
    }
    </script>
</head>
<body>
    <nav class="navbar">
        <div class="container">
            <div class="nav-brand">Sebastian Medina</div>
            <ul class="nav-menu">
                <li><a href="../index.html#about">About</a></li>
                <li><a href="../index.html#publications">Publications</a></li>
                <li><a href="../index.html#blog">Blog</a></li>
                <li><a href="../index.html#contact">Contact</a></li>
            </ul>
        </div>
    </nav>

    <div class="container">
        <article class="blog-post">
            <a href="../index.html#blog" class="back-link">
                <i class="fas fa-arrow-left"></i> Back to Blog
            </a>

            <div class="blog-post-header">
                <h1>Deep Dive: An AI-Based Pathology Classifier to Predict Docetaxel Benefit in Prostate Cancer</h1>
                <div class="blog-post-meta">
                    <span><i class="fas fa-calendar"></i> January 2025</span>
                    <span><i class="fas fa-tag"></i> computational pathology, prostate cancer, precision oncology</span>
                </div>
            </div>

            <div class="blog-post-content">
                <h2>A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer</h2>

                <p><strong>Authors:</strong> Sebastian Medina, Naoto Tokuyama, Kamal Hammouda, Tilak Pathak, Tuomas Mirtti, Pingfu Fu, Shilpa Gupta, Priti Lal, Howard M. Sandler, Rohann Correa, Susan Chafe, Amit Shah, Jason A. Efstathiou, Karen Hoffman, Michael Straza, Mark A. Hallman, Richard Jordan, Stephanie L. Pugh, Christopher J. Sweeney, and Anant Madabhushi</p>

                <p><strong>Published in:</strong> Clinical Cancer Research (2025)</p>

                <h2>The Clinical Challenge</h2>

                <p>
                    Docetaxel has transformed the treatment landscape for prostate cancer. Since the landmark CHAARTED and STAMPEDE trials, early docetaxel treatment has become a cornerstone therapy for patients with metastatic hormone-sensitive prostate cancer (mHSPC). More recently, docetaxel has emerged as a component of triplet therapy in combination with androgen receptor pathway inhibitors (ARPIs) and androgen deprivation therapy (ADT).
                </p>

                <p>
                    However, a critical clinical dilemma persists: <strong>not all patients benefit equally from docetaxel</strong>. While docetaxel improves outcomes for some patients, others are exposed to significant toxicities—including neurotoxicity, febrile neutropenia, and rare treatment-related mortality—without deriving meaningful benefit. Current patient selection relies primarily on clinical factors such as tumor burden and timing of metastasis, but treatment response remains heterogeneous even among carefully selected patients.
                </p>

                <p>
                    This raises a fundamental question: <strong>Can we identify, using routine diagnostic tissue, which patients will truly benefit from docetaxel chemotherapy?</strong>
                </p>

                <!-- IMAGE PLACEHOLDER 1: Graphical abstract or APIC pipeline overview -->
                <div style="background-color: #f0f0f0; border: 2px dashed #ccc; padding: 2rem; margin: 2rem 0; text-align: center; border-radius: 8px;">
                    <p style="color: #666; font-style: italic; margin: 0;">
                        <strong>IMAGE PLACEHOLDER 1:</strong><br>
                        Insert graphical abstract or Figure 1 showing the APIC pipeline overview
                    </p>
                </div>

                <h2>Study Design and Approach</h2>

                <p>
                    To address this challenge, Medina and colleagues developed and validated an <strong>artificial intelligence-based pathology image classifier (APIC)</strong> designed to predict docetaxel benefit using digitized hematoxylin and eosin (H&E)-stained biopsy specimens—the same slides already prepared for routine diagnosis.
                </p>

                <h3>The Hypothesis</h3>

                <p>
                    The investigators hypothesized that variations in nuclear morphology and the immune microenvironment—features visible in standard H&E slides—would predict differential docetaxel sensitivity. This hypothesis builds on emerging evidence that tumor-immune spatial interactions and cellular heterogeneity reflect underlying tumor biology that influences treatment response.
                </p>

                <h3>Trial Populations</h3>

                <p>The study analyzed specimens from two landmark phase III randomized clinical trials:</p>

                <ol>
                    <li><strong>CHAARTED (ECOG-ACRIN E3805):</strong> 286 of 790 patients with mHSPC, randomized to ADT alone versus ADT plus docetaxel</li>
                    <li><strong>NRG/RTOG 0521:</strong> 350 of 563 patients with high-risk localized prostate cancer, randomized to ADT plus radiotherapy alone versus ADT plus radiotherapy plus adjuvant docetaxel</li>
                </ol>

                <!-- IMAGE PLACEHOLDER 2: CONSORT flow diagrams -->
                <div style="background-color: #f0f0f0; border: 2px dashed #ccc; padding: 2rem; margin: 2rem 0; text-align: center; border-radius: 8px;">
                    <p style="color: #666; font-style: italic; margin: 0;">
                        <strong>IMAGE PLACEHOLDER 2:</strong><br>
                        Insert Figure 2 showing the CONSORT flow diagrams for patient selection in both trials
                    </p>
                </div>

                <h2>The APIC Methodology</h2>

                <h3>Feature Extraction Pipeline</h3>

                <p>APIC employs a sophisticated multi-step analysis of whole-slide images:</p>

                <p><strong>Step 1: Patch Extraction and Quality Control</strong><br>
                Digitized slides were divided into 1,024 × 1,024-pixel tiles, with automated quality screening using HistoQC followed by expert pathologist review to exclude artifacts and insufficient tissue.</p>

                <p><strong>Step 2: Cellular Detection and Classification</strong><br>
                A deep learning model identified and classified individual nuclei as lymphocytes or non-lymphocytes (tumor, epithelial, and stromal cells).</p>

                <p><strong>Step 3: Lymphocyte Arrangement Analysis</strong><br>
                The investigators constructed proximity-based graphs for lymphocytes and non-lymphocytes, creating cellular networks where individual cells served as vertices connected to neighbors based on distance thresholds. From these spatial networks, 350 quantitative features were extracted capturing:</p>
                <ul>
                    <li>Local cellular clustering patterns</li>
                    <li>Cell numbers per cluster and cluster-to-tissue area ratios</li>
                    <li>Local density distributions</li>
                    <li>Spatial interactions between cell types (relative densities, overlapping areas, distances between lymphocyte and non-lymphocyte populations)</li>
                </ul>

                <p><strong>Step 4: Nuclear Diversity Analysis</strong><br>
                Local nuclear graphs were created connecting proximal nuclei, measuring eight morphologic features per nucleus: area, major/minor axis lengths, eccentricity, equivalent diameter, solidity, perimeter, and circularity. Co-occurrence matrices quantified nuclear shape feature frequency within cellular neighborhoods to measure nuclear morphologic heterogeneity.</p>

                <p><strong>Step 5: Signature Development</strong><br>
                Cox proportional hazards with elastic net regularization identified the seven most frequently selected features across cross-validation, creating the final APIC signature.</p>

                <!-- IMAGE PLACEHOLDER 3: APIC pipeline with histology examples -->
                <div style="background-color: #f0f0f0; border: 2px dashed #ccc; padding: 2rem; margin: 2rem 0; text-align: center; border-radius: 8px;">
                    <p style="color: #666; font-style: italic; margin: 0;">
                        <strong>IMAGE PLACEHOLDER 3:</strong><br>
                        Insert Figure 1 showing the detailed APIC pipeline with histology examples
                    </p>
                </div>

                <h2>Key Results</h2>

                <h3>Metastatic Hormone-Sensitive Prostate Cancer (CHAARTED)</h3>

                <p>
                    In the overall CHAARTED validation cohort (n = 208), docetaxel addition showed a non-significant HR of 0.84 (95% CI, 0.58–1.23; P = 0.37) for overall survival. However, when stratified by APIC status, a striking divergence emerged:
                </p>

                <h4>APIC-Positive Patients (56% of cohort)</h4>
                <ul>
                    <li><strong>Significant OS improvement with docetaxel:</strong> HR 0.52 (95% CI, 0.32–0.85; P = 0.0075)</li>
                    <li>5-year OS: 40.2% with docetaxel vs. 15.9% with ADT alone</li>
                    <li>Absolute difference: <strong>24.3%</strong></li>
                    <li>Median survival: 4.1 years with docetaxel vs. 2.9 years with ADT alone</li>
                </ul>

                <h4>APIC-Negative Patients (44% of cohort)</h4>
                <ul>
                    <li><strong>No OS benefit from docetaxel:</strong> HR 1.31 (95% CI, 0.71–2.44; P = 0.39)</li>
                    <li>5-year OS: 40.9% with docetaxel vs. 55.6% with ADT alone</li>
                    <li>Absolute difference: <strong>-14.7%</strong> (numerically worse with docetaxel)</li>
                </ul>

                <p>
                    The <strong>treatment–APIC interaction was statistically significant (P = 0.022)</strong>, confirming APIC's predictive value.
                </p>

                <!-- IMAGE PLACEHOLDER 4: OS Kaplan-Meier curves CHAARTED -->
                <div style="background-color: #f0f0f0; border: 2px dashed #ccc; padding: 2rem; margin: 2rem 0; text-align: center; border-radius: 8px;">
                    <p style="color: #666; font-style: italic; margin: 0;">
                        <strong>IMAGE PLACEHOLDER 4:</strong><br>
                        Insert Figure 3A showing OS Kaplan-Meier curves stratified by APIC status in CHAARTED
                    </p>
                </div>

                <h3>Time to Castration Resistance (CHAARTED)</h3>

                <p>APIC also predicted benefit for delaying progression to castration-resistant prostate cancer:</p>

                <h4>APIC-Positive Patients</h4>
                <ul>
                    <li><strong>Significant delay in CRPC:</strong> HR 0.48 (95% CI, 0.33–0.71; P = 0.00019)</li>
                    <li>2-year CRPC-free survival: 34.6% with docetaxel vs. 15.4% with ADT alone</li>
                    <li>Absolute difference: <strong>19.1%</strong></li>
                </ul>

                <h4>APIC-Negative Patients</h4>
                <ul>
                    <li><strong>No improvement in time to CRPC:</strong> HR 1.08 (95% CI, 0.59–1.96; P = 0.8)</li>
                </ul>

                <p>Treatment–APIC interaction: <strong>P = 0.031</strong></p>

                <!-- IMAGE PLACEHOLDER 5: CRPC-free survival curves -->
                <div style="background-color: #f0f0f0; border: 2px dashed #ccc; padding: 2rem; margin: 2rem 0; text-align: center; border-radius: 8px;">
                    <p style="color: #666; font-style: italic; margin: 0;">
                        <strong>IMAGE PLACEHOLDER 5:</strong><br>
                        Insert Figure 3D showing CRPC-free survival curves by APIC status
                    </p>
                </div>

                <h3>High-Risk Localized Prostate Cancer (NRG/RTOG 0521)</h3>

                <p>
                    The overall NRG/RTOG 0521 validation cohort (n = 266) did not show significant survival benefit with docetaxel addition (HR 0.79; 95% CI, 0.50–1.24; P = 0.31). Again, APIC revealed hidden heterogeneity:
                </p>

                <h4>APIC-Positive Patients (45% of cohort)</h4>
                <ul>
                    <li><strong>Significant OS benefit:</strong> HR 0.49 (95% CI, 0.26–0.92; P = 0.023)</li>
                    <li>10-year OS: 74.4% with docetaxel vs. 52.7% with RT + ADT alone</li>
                    <li>Absolute difference: <strong>21.7%</strong></li>
                </ul>

                <h4>APIC-Negative Patients (55% of cohort)</h4>
                <ul>
                    <li><strong>No significant OS difference:</strong> HR 1.17 (95% CI, 0.59–2.30; P = 0.66)</li>
                    <li>10-year OS: 75.8% with docetaxel vs. 79.1% with RT + ADT alone</li>
                </ul>

                <p>Treatment–APIC interaction: <strong>P = 0.024</strong></p>

                <!-- IMAGE PLACEHOLDER 6: OS curves NRG/RTOG -->
                <div style="background-color: #f0f0f0; border: 2px dashed #ccc; padding: 2rem; margin: 2rem 0; text-align: center; border-radius: 8px;">
                    <p style="color: #666; font-style: italic; margin: 0;">
                        <strong>IMAGE PLACEHOLDER 6:</strong><br>
                        Insert Figure 3E showing OS curves in NRG/RTOG 0521 by APIC status
                    </p>
                </div>

                <h2>Multivariable Analysis: Independence from Clinical Factors</h2>

                <p>
                    A critical question for any biomarker is whether it provides information beyond existing clinical variables. In multivariable analyses adjusting for disease volume, timing of metastases, Gleason grade, PSA, and T stage:
                </p>

                <table style="width: 100%; border-collapse: collapse; margin: 1.5rem 0;">
                    <thead>
                        <tr style="background-color: var(--bg-light);">
                            <th style="border: 1px solid var(--border-color); padding: 0.75rem; text-align: left;">Endpoint</th>
                            <th style="border: 1px solid var(--border-color); padding: 0.75rem; text-align: left;">APIC Interaction HR</th>
                            <th style="border: 1px solid var(--border-color); padding: 0.75rem; text-align: left;">P-value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td style="border: 1px solid var(--border-color); padding: 0.75rem;">OS (CHAARTED)</td>
                            <td style="border: 1px solid var(--border-color); padding: 0.75rem;">0.39 (0.17–0.87)</td>
                            <td style="border: 1px solid var(--border-color); padding: 0.75rem;">0.022</td>
                        </tr>
                        <tr style="background-color: var(--bg-light);">
                            <td style="border: 1px solid var(--border-color); padding: 0.75rem;">CRPC (CHAARTED)</td>
                            <td style="border: 1px solid var(--border-color); padding: 0.75rem;">0.39 (0.19–0.81)</td>
                            <td style="border: 1px solid var(--border-color); padding: 0.75rem;">0.011</td>
                        </tr>
                        <tr>
                            <td style="border: 1px solid var(--border-color); padding: 0.75rem;">OS (NRG/RTOG 0521)</td>
                            <td style="border: 1px solid var(--border-color); padding: 0.75rem;">0.62 (0.39–0.98)</td>
                            <td style="border: 1px solid var(--border-color); padding: 0.75rem;">0.04</td>
                        </tr>
                    </tbody>
                </table>

                <p>
                    <strong>APIC remained independently predictive across all endpoints</strong>, demonstrating that it captures biological information not reflected in conventional clinical parameters.
                </p>

                <!-- IMAGE PLACEHOLDER 7: Multivariable analysis table -->
                <div style="background-color: #f0f0f0; border: 2px dashed #ccc; padding: 2rem; margin: 2rem 0; text-align: center; border-radius: 8px;">
                    <p style="color: #666; font-style: italic; margin: 0;">
                        <strong>IMAGE PLACEHOLDER 7:</strong><br>
                        Insert Table 2 showing multivariable analysis results
                    </p>
                </div>

                <h2>What Does APIC Capture Biologically?</h2>

                <p>
                    APIC showed weak or no correlation with Gleason score in both cohorts, suggesting it captures <strong>independent biological information</strong> that complements conventional risk stratification. The features driving APIC relate to:
                </p>

                <ol>
                    <li><strong>Tumor-Immune Spatial Architecture:</strong> The spatial arrangement and clustering of lymphocytes relative to tumor cells may reflect immune engagement patterns that influence chemotherapy response.</li>
                    <li><strong>Nuclear Morphologic Heterogeneity:</strong> Variations in nuclear shape, size, and arrangement within tumors may indicate underlying genomic instability or aggressive phenotypes that predict chemotherapy sensitivity.</li>
                </ol>

                <p>
                    Importantly, exploratory analyses showed APIC had weak to modest correlation with transcriptomic classifiers (Decipher, PAM50 luminal B), indicating it captures <strong>complementary biological information</strong> to genomic tests.
                </p>

                <h2>Clinical Implications</h2>

                <h3>Refining Patient Selection</h3>

                <p>The study's findings suggest APIC could help address several clinical scenarios:</p>

                <ol>
                    <li><strong>For APIC-Positive Patients with mHSPC:</strong> Strong consideration for docetaxel-containing regimens, as these patients derive substantial benefit. In the era of triplet therapy (ADT + ARPI + docetaxel), these may be ideal candidates for chemotherapy intensification.</li>
                    <li><strong>For APIC-Negative Patients with mHSPC:</strong> ARPI-based doublet therapy may be preferred, allowing patients to avoid chemotherapy toxicity without sacrificing outcomes.</li>
                    <li><strong>For High-Risk Localized Disease:</strong> APIC could identify the subset of patients (approximately 45%) who benefit from adjuvant docetaxel, potentially supporting shared decision-making in this setting where docetaxel benefit has been uncertain.</li>
                </ol>

                <h3>Practical Advantages</h3>

                <p>APIC offers several practical advantages for clinical implementation:</p>

                <ul>
                    <li><strong>Uses routine diagnostic tissue:</strong> No additional biopsies or specialized molecular testing required</li>
                    <li><strong>H&E slides are universally available:</strong> Applicable in resource-limited settings where transcriptomic testing may not be feasible</li>
                    <li><strong>Complements existing biomarkers:</strong> Can be used alongside or in lieu of genomic classifiers</li>
                </ul>

                <h2>Limitations and Future Directions</h2>

                <p>The investigators acknowledged several limitations:</p>

                <ol>
                    <li><strong>Retrospective analysis:</strong> While using the rigorous prospective-retrospective framework described by Simon et al., prospective validation remains needed.</li>
                    <li><strong>Sample size constraints:</strong> Quality control requirements excluded a substantial proportion of cases, potentially introducing selection bias.</li>
                    <li><strong>Focus on docetaxel doublet therapy:</strong> Validation in contemporary triplet regimens (ADT + ARPI + docetaxel) is an important next step.</li>
                    <li><strong>Single treatment comparison:</strong> Evaluation of whether APIC can guide selection between docetaxel-based and ARPI-only intensification strategies requires further study.</li>
                </ol>

                <h2>Conclusions</h2>

                <p>
                    Medina and colleagues present APIC as a promising AI-based biomarker that predicts docetaxel benefit in both metastatic and high-risk localized prostate cancer. Key takeaways include:
                </p>

                <ul>
                    <li><strong>APIC identifies patient subgroups with differential docetaxel benefit</strong> independent of clinical risk factors</li>
                    <li>In validation cohorts, <strong>44-55% of patients showed no significant benefit</strong> from docetaxel and could potentially be spared chemotherapy toxicity</li>
                    <li><strong>APIC-positive patients derived substantial benefit</strong> with absolute OS improvements of 21-24%</li>
                    <li>The biomarker's reliance on <strong>routine H&E slides</strong> enhances accessibility for clinical implementation</li>
                    <li><strong>Validation in triplet therapy regimens</strong> is needed to establish APIC's role in contemporary treatment paradigms</li>
                </ul>

                <p>
                    As treatment intensification options expand in advanced prostate cancer, tools like APIC may help clinicians navigate the increasingly complex therapeutic landscape and deliver truly personalized therapy.
                </p>

                <hr style="margin: 2rem 0; border: none; border-top: 1px solid var(--border-color);">

                <p><strong>Reference:</strong></p>
                <p>
                    Medina S, Tokuyama N, Hammouda K, et al. A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer. <em>Clin Cancer Res</em>. 2025.
                    <a href="https://doi.org/10.1158/1078-0432.CCR-25-3327" target="_blank">doi: 10.1158/1078-0432.CCR-25-3327</a>
                </p>
            </div>
        </article>
    </div>

    <footer class="footer">
        <div class="container">
            <p>&copy; 2025 Sebastian Medina. All rights reserved.</p>
        </div>
    </footer>
</body>
</html>
